Tenaya Therapeutics Inc（TNYA）股票分析TNYATenaya Therapeutics Inc

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tenaya Therapeutics Inc is not a good buy right now due to its poor financial performance and negative market sentiment. The current price is 0.3602, which is a drastic drop of 74.81% over the past year, indicating a lack of investor confidence. Additionally, the RSI is at 43.77, suggesting that the stock is neither overbought nor oversold but is trending downwards. The company has reported a net income loss of -43,393,000 in Q2 2026, which raises concerns about its financial health. The significant insider selling, which increased by 55,373.56% over the last month, further signals a lack of confidence from those within the company. The main risk is the stock's current low price, which is only 4.8% of its 52-week range, indicating a potential for further declines rather than recovery.